Diligence memo · auto-generated · as of July 2, 2026

Fera Diagnostics & Biologicals Corp.

Fera Diagnostics & Biologicals Corp. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Fera Diagnostics & Biologicals Corp. operates in Medical Devices, based in ITHACA.

Sub-sector tags: medical-devices.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Fera Diagnostics & Biologicals Corp. has raised $1.5M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $1.5M on 2021-01-27.

Most recent recorded round closed around 2021-01-27.

Valuation (modeled)modeled

Provath models Fera Diagnostics & Biologicals Corp. at approximately $34M (range $1.2M–$229M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.81× the median modeled value of Seed Medical Devices companies in 2019–2021 (23 peers) — value vs value, same stage and era. Within the normal band (81% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 5.4 yr ago; this sector typically re-raises about every 16 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 48% of Medical Devices peers (233 compared).

Modeled value ranks above 70% of those peers.

Closest niche peers: Gradian Diagnostics Inc, Regent Surgical Health Intermediate Holdings, Inc., Caliber Imaging & Diagnostics, Inc., Dxterity Diagnostics Inc, Sure Count Surgical, LLC.

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.